hC Bioscience has appointed Jose Lora, Ph.D., as its Chief Scientific Officer (CSO). In this position, Lora will play a pivotal role in helping to shape the Company’s strategic direction around its innovative portfolio of therapeutic tRNAs and advancing their lead candidates into the clinic.
Boston, Massachusetts--(Newsfile Corp. - September 25, 2023) - hC Bioscience has appointed Jose Lora, Ph.D., as its Chief Scientific Officer (CSO). In this position, Lora will play a pivotal role in helping to shape the Company’s strategic direction around its innovative portfolio of therapeutic tRNAs and advancing their lead candidates into the clinic.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- hC Bioscience has appointed Jose Lora, Ph.D., as its new Chief Scientific Officer.
- Lora’s expertise will help shape hC Bioscience’s research and development strategies with an initial focus on bringing the Company’s lead candidate for the treatment of cancer into the clinic.
- In addition, Lora will oversee the management of the Company’s development pipeline, prioritizing therapeutic applications, and expanding the platform to address additional types of mutations.
Click image above to view full announcement.
About hC Bioscience
hC Bioscience is dedicated to bringing tRNA-based therapies to patients. Therapeutic tRNA is a new class of treatments that target disease-causing proteins at the level of translation.
Our initial focus is designing and developing therapeutic tRNAs to treat cancers caused by gene mutations and inherited diseases. Our lead indications include colorectal cancer that has metastasized to the liver (CRCLM), inherited retinal disease such as retinitis pigmentosa, and muscular dystrophies.
Therapeutic tRNA represents the next-generation of RNA-based therapies. It holds the potential to repair or eliminate damaged proteins from the body by modifying errors in mRNA, a key molecule that translates genes into proteins.
hC Bioscience is Based in Boston, MA and was founded on technology out of Universities such as Iowa, Wisconsin, Rochester, and Chicago. The Company secured $40 million in series A financing with investments from leading venture firms including ARCH Ventures, Takeda Ventures, 8VC, Taiho Ventures, Panacea Venture, and CureDuchene.
Contacts:
Savannah Beaver
(617) 804-0366
savannah@reportablenews.com
Source: hC Bioscience
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/181787
